Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQE Share News (IQE)

Share Price Information for IQE (IQE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.15
Bid: 32.75
Ask: 33.30
Change: -2.50 (-7.01%)
Spread: 0.55 (1.679%)
Open: 36.25
High: 36.25
Low: 32.65
Prev. Close: 35.65
IQE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: IQE makes new epiwafers; Ilika sees sales delay

Wed, 11th May 2022 11:20

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

IQE PLC, up 10% at 31.57 pence, 12-month range 28.25p-55.00p. Notes first commercially available 200 millimetre VCSEL epiwafer, which is based on company's patented 200mm technology for wireless and photonics compound semiconductor applications. "IQE is leading the compound semiconductor industry in the development of 200mm epiwafers for wireless, sensing and display markets," it says. "IQE's 200mm epiwafers will enable a step-change in unit economics for compound semiconductors, leading to the expansion of the market for IQE. The increase in wafer size will expand to new foundry partnerships, including Silicon-based foundries." Chief Executive Americo Lemos says this is a "critical milestone".

----------

AIM - LOSERS

----------

Ilika PLC, down 21% at 75.00 pence, 12-month range 74.66p-220.48p. Trading in the financial year that ended April 30 was in line with management expectations but issues warning for 2023. Revenue in recent year estimated to be down to GBP500,000 from GBP2.3 million the year prior. Expects to report annual earnings before interest, taxes, depreciation, and amortization loss of GBP7.0 million versus earnings of GBP2.3 million in financial 2021. Looking ahead, notes its Stereax manufacturing site for miniature solid-state batteries is "taking longer than previously anticipated" to produce product batches that meet specification. Adds: "The shift in the weighting of customer demand towards medical device applications combined with the expectation of optimisation cycles continuing into H2 FY23, means the company now expects commercial sales to commence at the end of that period, later than originally anticipated."

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.